COMMUNIQUÉS West-GlobeNewswire

Erdem Health Group Enters Türkiye’s TURQUALITY Program
08/05/2026
The recognition supports Istanbul-based healthcare group’s international brand strategy and reinforces its quality-focused growth in health tourism Erdem Health Group has been accepted into TURQUALITY®, Türkiye’s state- [...]
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
08/05/2026
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including [...]
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
08/05/2026
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), [...]
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
08/05/2026
JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® today announced that [...]
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
08/05/2026
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of [...]
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
08/05/2026
SUNNYVALE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Alamar Biosciences Reports First Quarter 2026 Financial Results
08/05/2026
FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for [...]
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
08/05/2026
DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
08/05/2026
Patent Expands Company's Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue [...]
Prenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
08/05/2026
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today [...]
MIMEDX Announces Launch of G4Derm® Plus
08/05/2026
Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. ( [...]
J-Star Holding Signs MOU with White Group to Advance Financing for Texas Solid-State Battery Facility
08/05/2026
White Group to support capital formation for J-Star’s Baytown, Texas automated battery manufacturing project TAICHUNG CITY, Taiwan, May 08, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or [...]
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
08/05/2026
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated [...]
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
08/05/2026
- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application [...]
Merit Medical to Participate in the Bank of America Healthcare Conference
08/05/2026
SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will [...]
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
08/05/2026
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment [...]
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
08/05/2026
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it [...]
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08/05/2026
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
08/05/2026
Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in [...]

Pages